In all actual clinical guidelines, dihydropyridine calcium channel blockers (CCBs) belong to
the recommended first line antihypertensive drugs to treat essential hypertension. Several …

Lercanidipine is a dihydropyridine calcium channel blocker under FDA review for the
management of hypertension. It is a highly lipophilic compound with a long duration of …

Calcium-channel blockers (CCBs) have been used for the treatment of hypertension for
more than 20 years, and recent clinical trials support the efficacy and safety of long-acting …

Lercanidipine is a lipophilic, dihydropyridine calcium antagonist with a long receptor half-
life. Its slow onset of action helps to avoid reflex tachycardia associated with other …

Lercanidipine is a vasoselective dihydropyridine calcium antagonist which causes systemic
vasodilation by blocking the influx of calcium ions through L-type calcium channels in cell …

All studies suggesting a lower incidence of edema on lacidipine than on amlodipine are
based on subjective scoring. Therefore, we have compared edema formation on two …

The pharmacokinetic and pharmacodynamic profiles of lacidipine, a 1, 4-dihydropyridine
calcium antagonist, and the β-adrenoceptor blocker propranolol were determined alone and …

This article contains information concerning the aspects of pharmacokinetics and
pharmacodynamics of dihydropyridine calcium antagonists. The authors have discussed the …

Recent publications purporting to show that calcium antagonists, when used for the
treatment of hypertension or in the post myocardial infarction patient, would paradoxically …

Calcium antagonists continue to have a place in the treatment of hypertension, despite
recent concerns regarding their safety and long-term capacity to alter the natural history of …